SGMT · Sagimet Biosciences Inc.
$7.19
-0.08 (-1.10%)
At close · Jul 29
Market Cap
$448.94M
Shares
61.75M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David Happel | CEO | $3,239,994 |
| Elizabeth Rozek | Chief Legal and Administrative Officer | $1,496,702 |
| Eduardo Bruno Martins | Former Chief Medical Officer | $1,360,841 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Thierry Chauche | CFO | $2,407,476 |
| David Happel | CEO | $906,164 |
| Eduardo Bruno Martins | Former Chief Medical Officer | $669,064 |
| Elizabeth Rozek | Chief Legal and Administrative Officer | $626,142 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David Happel | CEO | $2,685,917 |
| Eduardo Bruno Martins | Former Chief Medical Officer | $1,509,081 |
| Thierry Chauche | CFO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Happel | CEO | $6,508,193 |
| George Kemble | CEO | $574,866 |
| Eduardo Bruno Martins | Former Chief Medical Officer | $537,130 |
| Dennis Hom | CFO | $466,892 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| George Kemble | Class III director | Appointed | 2026-06-12 |
| David Happel | Class III director | Appointed | 2026-06-12 |
| Anne Phillips | Class III director | Appointed | 2026-06-12 |
| Jennifer Jarrett | Class III director | Appointed | 2026-06-12 |
| Andreas Grauer, M.D. | Chief Medical Officer | Appointed | 2026-04-21 |
| Eduardo Martins, M.D., D.Phil. | Chief Medical Officer | Retired | 2026-04-21 |
Key facts
CIK
1400118
CUSIP
786700104
13F (30d)
12 filings
12 filers
Visit website
Investor relations